| 000 | 01139 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250515205258.0 | ||
| 264 | 0 | _c20100423 | |
| 008 | 201004s 0 0 eng d | ||
| 022 | _a1476-5381 | ||
| 024 | 7 |
_a10.1111/j.1476-5381.2009.00265.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGuth, B D | |
| 245 | 0 | 0 |
_aDealing with hERG liabilities early: diverse approaches to an important goal in drug development. _h[electronic resource] |
| 260 |
_bBritish journal of pharmacology _cJan 2010 |
||
| 300 |
_a22-4 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug-Related Side Effects and Adverse Reactions |
| 650 | 0 | 4 |
_aEther-A-Go-Go Potassium Channels _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLong QT Syndrome _xchemically induced |
| 650 | 0 | 4 |
_aRisk Assessment _xmethods |
| 700 | 1 | _aRast, G | |
| 773 | 0 |
_tBritish journal of pharmacology _gvol. 159 _gno. 1 _gp. 22-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1476-5381.2009.00265.x _zAvailable from publisher's website |
| 999 |
_c19512542 _d19512542 |
||